World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 October 2017
Main ID:  NCT00086684
Date of registration: 07/07/2004
Prospective Registration: No
Primary sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Public title: Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
Scientific title: Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis
Date of first enrolment: September 2003
Target sample size: 369
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/show/NCT00086684
Study type:  Interventional
Study design:   
Phase:  Phase 4
Countries of recruitment
Canada United States
Contacts
Name:     Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Clinical Trial
Address: 
Telephone:
Email:
Affiliation:  Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Key inclusion & exclusion criteria

Inclusion Criteria:

- Must have a total score of 8 or greater on the O'Leary-Sant Interstitial Cystitis
Symptom Index (ICSI) and a score of > 0 on each of the 4 questions on the ICSI

- must have experienced bladder pain, urinary urgency and urinary frequency, each not
related to a urinary tract infection, for at least 6 months prior to entry into the
study

- must have averaged >= 10 voids per day (>=30 voids over 3 consecutive days) and
averaged >= 1 void at night

- urine culture showing no evidence of urinary tract infection

- urine cytology showing no evidence of neoplastic cells

Exclusion Criteria:

- Scheduled for or use of intravesical therapy (eg, bladder distention, dimethyl
sulfoxide) during or within 4 weeks prior to the study

- patients who have had cytoscopic evaluation within 4 weeks prior to the study

- patients who are currently (within last month) receiving other medications that may
affect symptoms of interstitial cystitis (ie, antidepressants, antihistamines,
antispasmodics, anticholinergics)

- patients who are chronic users of Schedule II narcotics or who are using any scheduled
narcotics at the time of study entry

- patients taking coumadin, anticoagulants, heparin, or thrombolytic agents such as
tissue plasminogen activator and streptokinase



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Interstitial Cystitis
Intervention(s)
Drug: Placebo
Drug: Pentosan polysulfate sodium 100 mg
Primary Outcome(s)
Number of Responders Defined as Having at Least a 30% Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study Endpoint [Time Frame: Baseline to Week 24]
Secondary Outcome(s)
Number of Responders Defined as Having at Least a Four Point Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study Endpoint [Time Frame: Baseline to Week 24]
Secondary ID(s)
C-2002-036
CR004576
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 06/07/2012
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT00086684
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history